Evidence map›Paper›PMID 35740381›Full record

ArticleBiomedicines2022

A Comparative Study of Cell Culture Conditions during Conversion from Primed to Naive Human Pluripotent Stem Cells.

Irene Romayor, Lara Herrera, Maria Burón, Myriam Martin-Inaraja, Laura Prieto, Jone Etxaniz, Marta Inglés-Ferrándiz, Jose Ramon Pineda, Cristina Eguizabal

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Irene RomayorCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Lara HerreraCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Maria BurónCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Myriam Martin-InarajaCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Laura PrietoCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-9486-7403
Jone EtxanizCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Marta Inglés-FerrándizCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0003-1531-7791
Jose Ramon PinedaCell Biology and Histology Department, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0002-0900-7466
Cristina EguizabalCell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-8738-2077
Basque Center for Materials, Applications and Nanostructures · ESUniversity of the Basque Country · ES

Funding

Economic Development and Infrastructures Department of the Basque Government (KK-2020/00068)EITB Maratoia (BIO21/COV/030)Health Department of the Basque Government 2019111068, 2019/4703, 2020111058, 2020333032 and 2021333012Instituto de Salud Carlos III and co-funded by European Union (ERDF) "A way to make Europe" Project "PI18/01299" and "PI21/01187"Instituto de Salud Carlos III and co-funded by European Union (NextGenerationEU) "ICI21/00095"I.R was supported by Margarita Salas Grant "MARSA21/60".". L.H. was supported by the Jesus Gangoiti Barrera Foundation and the Asociación Española contra el Cáncer (AECC) and the Fundación Mutua Madrileña.Merck-Salud Foundation (FSALUD17/004)M.M-I was supported by Jesus Gangoiti Barrera Foundation.RICORS: Red Española de Terapias Avanzadas TERAV ISCIII. Instituto de Salud Carlos III (ISCIII) and co-funded by European Union (NextGenerationEU) "Plan de Recuperación Transformación y Resiliencia" (RD21/00017/0024)
6 · The paper itself

Abstract

The successful reprogramming of human somatic cells into induced pluripotent stem cells (hiPSCs) represented a turning point in the stem cell research field, owing to their ability to differentiate into any cell type with fewer ethical issues than human embryonic stem cells (hESCs). In mice, PSCs are thought to exist in a naive state, the cell culture equivalent of the immature pre-implantation embryo, whereas in humans, PSCs are in a primed state, which is a more committed pluripotent state than a naive state. Recent studies have focused on capturing a similar cell stage in human cells. Given their earlier developmental stage and therefore lack of cell-of-origin epigenetic memory, these cells would be better candidates for further re-differentiation, use in disease modeling, regenerative medicine and drug discovery. In this study, we used primed hiPSCs and hESCs to evaluate the successful establishment and maintenance of a naive cell stage using three different naive-conversion media, both in the feeder and feeder-free cells conditions. In addition, we compared the directed differentiation capacity of primed and naive cells into the three germ layers and characterized these different cell stages with commonly used pluripotent and lineage-specific markers. Our results show that, in general, naive culture NHSM medium (in both feeder and feeder-free systems) confers greater hiPSCs and hESCs viability and the highest naive pluripotency markers expression. This medium also allows better cell differentiation cells toward endoderm and mesoderm.

Indexed as

cell differentiationectodermendodermhESCshiPSCsmesodermnaive statuspluripotencyprimed status

Identifiers

PMID35740381
PMCPMC9219795
OpenAlexW4281808878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.